Company Profile
Arcutis Biotherapeutics Stock Price, News & Analysis
Company overview
Business overview
Arcutis Biotherapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Arcutis Biotherapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Arcutis Biotherapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Arcutis Biotherapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
ARQT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Arcutis's catalysts are ZORYVE expansion and dermatology-launch execution, especially in inflammatory skin disease where label breadth matters. The market wants to see whether the dermatology franchise can keep widening.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Arcutis Biotherapeutics
- 02
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
Source: Arcutis Biotherapeutics
- 03
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
Source: Arcutis Biotherapeutics
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.